Literature DB >> 11209117

Treatment of prurigo nodularis with topical capsaicin.

S Ständer1, T Luger, D Metze.   

Abstract

BACKGROUND: Prurigo nodularis is an eruption of lichenified or excoriated nodules caused by intractable pruritus that is difficult to treat. Therefore the antipruritic efficacy of capsaicin seemed to be of particular interest because this alkaloid, extractable from red pepper, interferes with the perception of pruritus and pain by depletion of neuropeptides in small sensory cutaneous nerves.
OBJECTIVE: The aim of this concentration- and regimen-ranging study was to evaluate the efficacy, safety, and practicability of capsaicin in the topical treatment of prurigo nodularis in a large series of patients.
METHODS: A total of 33 patients with prurigo nodularis of various origins were selected to receive capsaicin (0.025% to 0.3%) 4 to 6 times daily for 2 weeks up to 10 months. The consecutive follow-up period was up to 6 months. In 7 patients, skin biopsy specimens were taken before, during, and after therapy and investigated histologically, immunohistochemically, and ultrastructurally.
RESULTS: All 33 patients could be evaluated for efficacy. After cessation of the symptoms of neurogenic inflammation, such as burning sensations or erythema, all of them experienced a complete elimination of pruritus within 12 days. In addition, capsaicin largely contributed to the gradual healing of the skin lesions. After discontinuation of the therapy, pruritus returned in 16 of 33 patients within 2 months. At the ultrastructural level, no degenerative changes of cutaneous nerves could be found during or after capsaicin therapy. Depletion of substance P was demonstrated by confocal laser scanning microscopy thus confirming the specific effect of capsaicin in vivo.
CONCLUSION: Topical treatment of prurigo nodularis with capsaicin proved to be an effective and safe regimen resulting in clearing of the skin lesions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11209117     DOI: 10.1067/mjd.2001.110059

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  21 in total

Review 1.  Transient receptor potential channels in pain and inflammation: therapeutic opportunities.

Authors:  Mark A Schumacher
Journal:  Pain Pract       Date:  2010-03-02       Impact factor: 3.183

Review 2.  TRP channels in the skin.

Authors:  Balázs I Tóth; Attila Oláh; Attila Gábor Szöllősi; Tamás Bíró
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 3.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

Authors:  Nicholas K Mollanazar; Peter K Smith; Gil Yosipovitch
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

4.  Chronic pruritus: clinics and treatment.

Authors:  Sonja Grundmann; Sonja Ständer
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

Review 5.  [New treatment options for chronic pruritus].

Authors:  C Zeidler; B Pfleiderer; S Ständer
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

6.  A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control.

Authors:  Eniko Bodó; Tamás Bíró; Andrea Telek; Gabriella Czifra; Zoltán Griger; Balázs I Tóth; Alessandra Mescalchin; Taisuke Ito; Albrecht Bettermann; László Kovács; Ralf Paus
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

7.  [Chronic prurigo].

Authors:  M P Pereira; T Nau; C Zeidler; S Ständer
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

Review 8.  Management of itch in atopic dermatitis.

Authors:  Judith Hong; Joerg Buddenkotte; Timothy G Berger; Martin Steinhoff
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 9.  Trp channels and itch.

Authors:  Shuohao Sun; Xinzhong Dong
Journal:  Semin Immunopathol       Date:  2015-09-18       Impact factor: 9.623

Review 10.  [Rational symptomatic therapy for chronic pruritus].

Authors:  S Ständer
Journal:  Hautarzt       Date:  2006-05       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.